- Home
- ICON vs QNRX Comparison
ICON vs QNRX Comparison
Compare ICON & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- QNRX
- Stock Information
- Founded
- ICON 2023
- QNRX 2018
- Country
- ICON Greece
- QNRX United States
- Employees
- ICON N/A
- QNRX N/A
- Industry
- ICON
- QNRX Medical/Dental Instruments
- Sector
- ICON
- QNRX Health Care
- Exchange
- ICON Nasdaq
- QNRX Nasdaq
- Market Cap
- ICON 3.6M
- QNRX 3.3M
- IPO Year
- ICON 2024
- QNRX N/A
- Fundamental
- Price
- ICON $1.68
- QNRX $8.82
- Analyst Decision
- ICON Strong Buy
- QNRX
- Analyst Count
- ICON 1
- QNRX 0
- Target Price
- ICON $4.50
- QNRX N/A
- AVG Volume (30 Days)
- ICON 62.0K
- QNRX 522.9K
- Earning Date
- ICON 06-17-2025
- QNRX 05-13-2025
- Dividend Yield
- ICON 206.67%
- QNRX N/A
- EPS Growth
- ICON N/A
- QNRX N/A
- EPS
- ICON N/A
- QNRX N/A
- Revenue
- ICON $5,309,000.00
- QNRX N/A
- Revenue This Year
- ICON $76.76
- QNRX N/A
- Revenue Next Year
- ICON $30.43
- QNRX N/A
- P/E Ratio
- ICON N/A
- QNRX N/A
- Revenue Growth
- ICON 18.61
- QNRX N/A
- 52 Week Low
- ICON $1.60
- QNRX $5.01
- 52 Week High
- ICON $154.00
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- QNRX 57.93
- Support Level
- ICON N/A
- QNRX $8.67
- Resistance Level
- ICON N/A
- QNRX $9.30
- Average True Range (ATR)
- ICON 0.00
- QNRX 0.62
- MACD
- ICON 0.00
- QNRX 0.03
- Stochastic Oscillator
- ICON 0.00
- QNRX 56.63
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a Growth-oriented company that operates as a holding company for the purpose of acquiring, owning, chartering and operating dry bulk vessels through its subsidiaries. The company generates its revenues by chartering the Initial Vessels to regional and international dry bulk operators, commodity traders and end users.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.